Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Exact Sciences Revenue Rises 23%—Shareholders Set to Vote on $23B Abbott Deal

February 15, 2026

Exact Sciences reported 23% year-over-year revenue growth for Q4 2025 and confirmed a special shareholder vote on its proposed $23 billion acquisition by Abbott. The company posted $878.4 million...

BridgeBio’s Infigratinib Matches Voxzogo on Height: Oral FGFR3 Option Emerges

February 15, 2026

BridgeBio reported data showing its oral FGFR3 inhibitor infigratinib achieved height outcomes comparable to Voxzogo in achondroplasia, positioning an oral therapy as an alternative to existing...

FDA Setback on Disc: Questions Grow About Accelerated Approval Vouchers

February 15, 2026

BioCentury reports the FDA issued a complete response letter (CRL) to Disc, reinforcing a pattern of regulators rejecting biomarker-based approvals and raising doubts about the accelerated...

Anterior Raises $40M: AI to Speed Care Approvals from Weeks to Minutes

February 15, 2026

Anterior raised $40 million to expand its AI platform that automates administrative clinical work for health plans, aiming to reduce prior-authorization and utilization review timelines from weeks...

Droplet digital PCR... Absolute quantification without standard curves

February 15, 2026

Bio-Rad’s digital PCR technology eliminates dependence on standard curves by partitioning samples into thousands of droplets and using Poisson statistics to count target molecules directly,...

GaAs detector boosts 100 keV cryo‑EM — higher-resolution imaging for biology

February 15, 2026

Researchers unveiled a hybrid-pixel gallium arsenide (GaAs) counting detector optimized for 100 keV electron beams that improves imaging performance for cryo-electron microscopy (cryo-EM). The new...

Drinkable foam delivers gene therapy: New oral route targets esophageal cancer

February 15, 2026

Researchers led by Stephan, Cummings, and Fitzgerald reported a novel orally administered foam that delivers gene therapy locally to constrictive esophageal carcinoma, enabling targeted...

Cells’ own packages repurposed: Extracellular vesicles for safer gene delivery

February 15, 2026

Researchers outlined strategies to harness extracellular vesicles (EVs) as nonviral carriers for gene and protein delivery, positioning EVs as an alternative to traditional viral vectors that can...

GLP‑1 activates KATP channels—pericyte mechanism shields heart

February 15, 2026

A Nature Communications study found glucagon‑like peptide‑1 (GLP‑1) activates ATP-sensitive potassium (KATP) channels in coronary pericytes, revealing a previously unrecognized cardioprotective...

Ferroptosis nanotherapy reverses CAFs: Remodels colorectal tumor stroma

February 15, 2026

Researchers led by Wang and colleagues reported a ferroptosis-based nanotherapy that selectively targets colorectal cancer–associated fibroblasts (CAFs), reprogramming the tumor microenvironment...

Exact Sciences Posts Strong Quarter – Shareholders Set to Vote on $23B Abbott Deal

February 15, 2026

Exact Sciences reported a 23% year-over-year revenue increase in Q4 2025 and is moving toward shareholder approval of Abbott Laboratories’ proposed $23 billion acquisition. The company posted...

FDA Rejects Disc’s Rare-Disease Drug: Voucher Program Faces First Test

February 15, 2026

The FDA rejected Disc Medicine’s bitopertin for a rare blood disorder, citing uncertainties about whether the trial biomarker correlates with clinical benefit, according to STAT. Bitopertin was...

BridgeBio’s Oral Infigratinib Matches Voxzogo on Height – Adds Patient‑Friendly Option

February 15, 2026

BridgeBio reported data showing its FGFR3 inhibitor infigratinib produced height gains comparable to Voxzogo (vosoritide) in patients with achondroplasia while offering an oral dosing option,...

Vertex Sees Casgevy Uptick – Gene‑Edited Therapy Bolsters Results

February 15, 2026

Vertex reported a rebound in sales for Casgevy, the gene‑edited therapy developed with CRISPR Therapeutics, with quarterly sales more than tripling versus the prior quarter. Management cited the...

PTC Withdraws Translarna FDA Bid – Data Gaps Cited

February 15, 2026

PTC Therapeutics said it will stop pursuing FDA approval for Translarna (ataluren) after regulators indicated the submitted data are unlikely to meet the agency’s threshold for substantial...

Australia Launches First Pediatric mRNA Brain‑Cancer Trial

February 15, 2026

Australia opened Paedneo‑Vax, the world’s first multisite pediatric trial testing individualized mRNA vaccines for aggressive brain tumors, funded by Providence Therapeutics, the Australian...

Anterior Raises $40M to Automate Care Approvals with AI

February 15, 2026

Anterior closed a $40 million financing to scale an AI platform that automates administrative care-authorization work for health plans, MedCity News reported. The company says its system can...

Agios Advances Mitapivat, Tebapivat in Sickle‑Cell After Thalassemia Win

February 15, 2026

After a regulatory success in thalassemia, Agios is preparing to present mixed Phase III Rise Up data for mitapivat and tebapivat to the FDA as it seeks full approval in sickle‑cell disease, the...

NIH’s All of Us Tops 1 Million — Representative Genomic Resource Achieved

February 15, 2026

The NIH announced that its All of Us research program has reached 1 million participants, meeting its goal of creating a diverse, population‑representative dataset of genomic and health data. The...

NIAID Restructures: Biodefense and Pandemic Prep Deprioritized, Emails Show

February 15, 2026

Nature reported that staff at the National Institute of Allergy and Infectious Diseases were directed to remove references to 'biodefense' and 'pandemic preparedness' from the institute’s web...